anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
At present, the prevention of hepatitis B recurrence after liver transplantation is the most commonly used scheme for nucleoside analogue combined hepatitis B immune globulin (HBIG). HBIG is a condensed to prevent the efficient price of invasion of hepatitis b immunoglobulin, its function is a direct and virus.Also it is to block the virus into liver cells. Lamivudine with HBIG therapy has hepatitis b recurrence rate reduced to below 10%, entecavir combined HBIG hepatitis b recurrence rate is low below 1%. In European and American countries, HBIG the most commonly used method for long-term high-dose intravenous drip, but our country is long-term low-dose intramuscular injection, but all need lifelong medication, for how long after surgery or which patients can disable or not HBIG no consensus. Whether long-term intravenous drip or intramuscular HBIG, are some disadvantages such as high cost, drug side effects, also brought inconvenience to patients. The advent of potent against hepatitis b virus drugs continuously under the background of, in recent years, scholars have already begun to no application or short-term application HBIG discontinuation to prevent hepatitis b recurrence after research, low before transplantation of hepatitis B virus(HBV) DNA replication, such as effective antiviral therapy of hepatitis b recurrence after after transplantation were created the conditions of no HBIG solution. Most studies suggest that transplantation of nucleoside analogues alone for a long time without application or short-term application of HBIG scheme to prevent hepatitis b recurrence is safe, but there are only several transplant center in study abroad, and the Chinese mainland for all application or short-term application of HBIG clinical studies. Entecavir with potent antiviral capacity and high genetic barrier to resistance, low incidence of drug resistance, is currently the prevention and treatment of hepatitis b recurrence after liver transplantation of first-line drugs, entecavir combined long-term muscle injection low-dose HBIG is at present our country is the most commonly used drug for liver transplantation in our center.

This study for entecavir combined after liver transplantation for short-term application type static note HBIG to prevent hepatitis b recurrence of prospective, multicenter, randomized, controlled experimental study, the equivalence. The purpose of this study is to observe a new scheme can achieve is the same as the traditional scheme of the effect of preventing hepatitis B recurrence.
The emulsion consists of oil phase, in form of globules dispersed in aqueous phase. Oil phase constitutes at least 15 wt.% per total wt. of emulsion. Aqueous phase contains at least one copolymer (C) composed of main fraction of 3-6C carboxylic acid monomer with mono-olefin unsaturation, or its anhydride, and minor fraction of acrylic acid fatty chain ester monomer; and contains no surfactant. The emulsion consists of oil phase, in form of globules of average size below 20 (preferably 0.5-15) microns dispersed in aqueous phase. Oil phase constitutes at least 15 wt.% per total wt. of emulsion. Aqueous phase contains at least one copolymer (C) composed of main fraction (80-98 wt.%) of 3-6C carboxylic acid monomer with mono-olefin unsaturation, or its anhydride, and minor fraction (2-20 wt.%, per total wt. of two monomers) of acrylic acid fatty chain ester monomer; and contains no surfactant.  Independent claims are also included for: (1) The use of emulsion as claimed in treatment, protection, care and/or cleaning of skin, mucous membranes and/or hair, and/or for make-up of skin and mucous membranes, and also in production of dermatological compositions for treatment and/or protection of skin, mucous membranes and/or hair; and (2) process of making the emulsion as claimed, comprising introducing oil phase under pressure higher than critical pressure (preferably 30-350 kPa) into aqueous phase containing copolymer, through porous glass membrane having average pore size 0.1-5 (preferably 0.3-3) microns.
In studies in which dronedarone was administered to rats and mice for up to 2 years at doses of up to 70 mg/kg/day and 300 mg/kg/day, respectively, there was an increased incidence of histiocytic sarcomas in dronedarone-treated male mice (300 mg/kg/day or 5× the maximum recommended human dose based on AUC comparisons), mammary adenocarcinomas in dronedarone-treated female mice (300 mg/kg/day or 8× MRHD based on AUC comparisons) and hemangiomas in dronedarone-treated male rats (70 mg/kg/day or 5× MRHD based on AUC comparisons).

Dronedarone did not demonstrate genotoxic potential in the in vivo mouse micronucleus test, the Ames bacterial mutation assay, the unscheduled DNA synthesis assay, or an in vitro chromosomal aberration assay in human lymphocytes. S-9 processed dronedarone, however, was positive in a V79 transfected Chinese hamster V79 assay. 

In fertility studies conducted with female rats, dronedarone given prior to breeding and implantation caused an increase in irregular estrus cycles and cessation of cycling at doses ≥10mg/kg (equivalent to 0.12× the MRHD on a mg/m2 basis).

Corpora lutea, implantations and live fetuses were decreased at 100 mg/kg (equivalent to 1.2× the MRHD on a mg/m2 basis). There were no reported effects on mating behavior or fertility of male rats at doses of up to 100 mg/kg/day.
Background: Breast cancer-related lymphedema (BCRL) remains a significant postcancer treatment challenge with no definitive cure. Recent supermicrosurgical treatments, such as lymphovenous anastomosis (LVA), have shown promise but lack established objective indicators for outcome evaluation. We investigated the utility of Technetium-99m (Tc-99m) lymphoscintigraphy, an imaging technique providing objective information on lymphatic fluid flow, for assessing LVA surgical outcomes. Methods and Results: A retrospective cohort analysis of patients undergoing LVA for BCRL was conducted. Lymphoscintigraphy images pre- and 1-year postsurgery were compared to determine changes in lymphatic fluid flow of 18 patients based on newly defined parameters "uptake ratio" and "washout rates." Statistically significant reduction in the uptake ratio was observed in the forearm at 30 and 60 minutes postinjection phases. In addition, the forearm showed higher washout rate, indicating an improved lymphatic function in the forearm. Conclusion: Tc-99m lymphoscintigraphy can provide valuable objective data for evaluating LVA surgical outcomes in BCRL patients. However, site-specific differences in outcomes highlight the need for individualized surgical planning. Further large-scale studies are necessary to validate these preliminary findings and develop a standardized approach for LVA assessment.
Participants randomized to the Experimental Group will submit a video of surgical performance of vaginal cuff closure during a hysterectomy. Subjects in the experimental group will then receive feedback within 5 business days of video submission and repeat the process of video submission of the same procedure using the same surgical approach every 2 weeks for 2 cycles. At 6 weeks, participants will submit a final video performing vaginal cuff closure during hysterectomy.
A composition comprises honey and collagen. Preferably the composition is for use in the treatment of a wound, in particular, a burn. The collagen is preferably bovine collagen and the honey is preferably of Unique Manuka Factor (UMF) +16. Preferably the composition comprises a mixture of an aqueous honey solution and an aqueous collagen suspension where the mixture comprises about 0.05% to 5.0% honey by weight. The composition may be in the form of a thin film or scaffold. An island dressing comprising the honey and collagen composition surrounded by an additional supporting thin film is outlined. A method of producing a honey collagen composition comprising the steps of preparing a collagen suspension, preparing a honey solution, and adding the honey solution to the collagen suspension is outlined. The suspension may be subjected to further steps of: optionally degassing, and drying at low temperatures or at higher temperatures to provide a thin film; lyophilisation or freeze-drying to form a porous sponge or membrane; or physical or chemical cross-linking. The composition is preferably administered topically to the skin.
Participants walk at 5,5 km/h on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at low lung volume with a density of 15 seconds, followed by a normal breath of 10 seconds (15 cycles of 15s apnea - 10s normal breathing, until completing the 6 minutes).
Hepatocellular carcinoma (HCC) is associated with higher mortality as a result of poor prognosis and unavailability of effective treatment options. This study retrospectively analyzed the clinical value of platelet-to-lymphocyte ratio (PLR) to aid in differentiating early hepatocellular carcinoma from liver cirrhosis patients. Three hundred and nine (309) patients including 155 patients with hepatocellular carcinoma (HCC) and 154 patients with liver cirrhosis were enrolled in this study. General clinical characteristics and blood parameters of each patient were collected, calculated, and retrospectively analyzed. Mann-Whitney U test was calculated to compare the two groups. Receiver operating characteristics (ROC) curve was performed to investigate the diagnostic potential of PLR in the prediction of HCC at a cut-off with high accuracy (area under the curve [AUC]) > 0.80. Hemoglobin (HB) concentration, red blood cell (RBC) count, neutrophil (NEU) count, platelet count, platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) were significantly higher in the HCC patients than in the liver cirrhosis patients (p < 0.05). ROC curve analysis showed that the AUC, optimal cut-off value, sensitivity, and specificity of PLR to predict HCC patients were 0.912, 98.7, 81.2%, and 80.6% respectively. The results suggest that PLR is a potential biomarker that can be used to predict early HCC.
PURPOSE: A polymer micelle drug composition is provided to effectively solubilize pioglitazone, rosiglitazone and troglitazone which are insoluble drugs. CONSTITUTION: A polymer micelle drug composition comprises amphiphilic diblock copolymer and one kind of insoluble drug. The amphiphilic diblock copolymer comprises hydrophilic block and one kind of hydrophobic block. The hydrophilic block contains polyakylene glycol. The hydrophobic block is selected among a group of polylactide, polyglycolide and their copolymer. The insoluble drug is selected among a group of pioglitazone, rosiglitazone, troglitazone and their mixture.
In addition to standard preparation, patients receive an access to a chatbot which can be contacted via Whats App starting at 3 days before colonoscopy. The chatbot is programed to answer questions concerning bowel preparation and colonoscopy conduct.
Patients undergo hypofractionated radiation boost over 2 fractions (at least 40 hours apart) during week 1. Beginning week 2, patients receive cisplatin IV on days 8, 15, 36, and 43; and etoposide IV over 60 minutes on days 8-12 and 36-40. Patients also undergo standard 3-D conformal radiation therapy QD 5 days a week for a total of 30 fractions. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
Comparator used as a control. 20 participants will be randomised to receive three monthly inoculations of the comparator.
Participants with non-FL iNHL (ie, participants with LPL/WM, SLL, or MZL), receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
PURPOSE: An effervescent and rapid disintegrating tablet containing mastic and water soluble polymer is provided to reduce weakness of table such as sticking and dissolve the drug in small amount of water. CONSTITUTION: An effervescent and rapid disintegrating tablet contains mastic which is sap extract of Pistasia lentiscus, water soluble polymer, sugar or their mixture. The tablet contains acid and carbonate. The tablet further contains sweetener. The water soluble polymer is contained in 0.2-10 weight parts based on mastic weight. The tablet contains 20-70 weight% of solid dispersion, 5-10 weight% of organic acid, and 5-15 weight% of carbonate.
BACKGROUND: Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), acting as one common sepsis-associated organ injury, induces uncontrolled and self-amplifies pulmonary inflammation. Given the lack of clinically effective approaches, the mortality rate of it still remains high. Suramin(SUR), as an antiparasitic drug initially, was found to ameliorate sepsis associated ALI in our previous work. However, the underlying mechanism of its protective effects has not been clarified. Pyroptosis, categorized as an inflammatory form of programmed cell death, could aggravate lung inflammatory responses via inducing alveolar macrophages (AM) pyroptosis.
METHODS: MH-S AM cell line was stimulated with or without lipopolysaccharide (LPS) or suramin, and the differential expression genes (DEGs) were excavated using RNA sequencing (RNA-seq). To identify the regulatory roles of these genes, pyroptosis-related genes (PRGs), GO/KEGG and GSEA analysis were conducted. We also performed WB, qRTPCR and ELISA to validate the RNA-seq results and further expound the protective effect of suramin.
RESULTS: 624 DEGs were identified between control (CON) and lipopolysaccharide (LPS) groups, and enrichment analysis of these genes revealed significantly enriched pathways that related to immune system and signal transduction. Meanwhile, 500 DEGs were identified in LPS/SUR+LPS group. In addition to the pathways mentioned above, IL-17 pathway and C-type lectin receptor signaling pathway were also enriched. All 6 pathways were connected with pyroptosis. Concurrently, the "DESeq2" R package was used to identify differentially expressed PRGs. Nod1, Nod2, interleukin (IL)-1b, IL-6, tumor necrosis factor (TNF), NLRP3 were upregulated under LPS stimulation. Then, in SUR+LPS group, Nod2, IL-6, IL-1b, NLRP3 were downregulated. The validation results of WB, qRT-PCR, and ELISA showed: the protein and mRNA expression levels of NLRP3, caspase-1, GSDMD and the concentrations of IL-1b, IL-18 were decreased when treated with suramin and LPS.
CONCLUSION: Suramin could inhibit NLRP3/caspase-1/GSDMD canonical pyroptosis pathway in LPS-induced MH-S alveolar macrophages.
PURPOSE:To obtain an antiallergic drug comprising a specific flavonoid contained in Morus Ihou of crude drug, Glycyrrhiza uralensis of crude drug or Epimedium macranthum var. violaceum. CONSTITUTION:An antiallergic drug containing a compound shown by formula I [R1 is H, hydroxyphenyl, etc.; R2 is 3-methyl-2-butenyl, methoxyphenyl, etc.; R3 is H or 3-methyl-2-butenyl; R4 is R3, group shown by formula II (Y is R3)], group shown by formula III (R5 is 3-methyl-2-butenyl or 3-hydroxy-3-methylbutyl), formula IV (R6 is group shown by formula V, formula VI, etc.), formula IV, formula VIII or formula IX (R8 is group shown by formula X or formula XI) obtained from an extract of Morus Ihou, Glycyrrhiza uralensis, Epimedium macranthum var. violaceum or homologous plant thereof in an organic solvent and having inhibitory action on 5-lipoxygenase, inhibitory action on cyclooxygenase and inhibitory action on hyaulronidase as an active ingredient. The compound is also useful as an anti-inflammatory drug, drug for circulatory organs, etc.
Starch propionate for humans is provided for weight loss and prevention of overweight and obesity. Starch propionate functions as a platform for delivery of propionic acid in the colon. It passes un-degraded to the colon, where propionic acid is released. Propionic acid in the colon stimulates the intestinal membrane to release appetite suppressing hormones GLP-1,(GLP-2) and PPY that reduces calorie intake and inhibits the production of fat in the liver and fat-tissue. Increased propionic acid in the blood inhibits fat production in the liver and fat-tissue. It also promotes the development of the gastrointestinal tract. Starch propionate can be used to reduce the appetite and calorie intake in humans.
FIELD: organic chemistry, chemical technology, pharmacy. SUBSTANCE: invention relates to novel substituted derivatives of benzenesulfonylurea or benzene-sulfonylthiourea of the formula (I)   and to their pharmaceutically acceptable salts also exhibiting antiarrhythmic activity and activity for prevention of sudden death caused by arrhythmia in heart stop, method of their synthesis, pharmaceutical composition containing thereof and method of its preparing. In compounds of the formula (I) R 1  means methyl; R 2  means C 4-10 -alkoxyl-group where from one to 6 carbon atoms are substituted for oxygen atom; E means oxygen or sulfur atom; X means hydrogen, halogen atom, C 1-6 -alkyl; or Y means [C(R 3 ) 2 ] 1-4  where R 3  means hydrogen atom; Z means C 1-4 -alkoxyl-group. Invention proposes method of synthesis of compound of the formula (I) where E means sulfur atom that involves interaction of sulfonamide of the formula (II)   or its salt of the formula (III)   with thiocyanate of the formula (IV)   where R 1 , R 2 , R 3 , Z, X and Y have said values and M means cation of alkaline or alkaline-earth metal, ammonium or tetraalkylammonium. Synthesized compound of the formula (I) where E means sulfur atom can be converted in the presence of oxidizing agent to compound of the formula (I) where E means oxygen atom. Pharmaceutical composition comprises effective amount of compound of the formula (I) or its pharmaceutically acceptable salt as active component and pharmaceutically acceptable additions. Composition is prepared by mixing effective amount of compound of the formula (I) or its pharmaceutically acceptable salt with at least one carrier or accessory substance up to useful dosing form preparing. EFFECT: improved method of synthesis and preparing. 12 cl, 4 ex
Opioid analgesics have been used to control the pain. However, many postoperative complication, such as nausea, vomiting, constipation, ileus, etc are related to opioid usage. Recently, local or regional pain nerve block, such as transversus abdominis plane block, wound infiltration, have been reported in several studies. Quadratus lumborum (QL) block was first introduced in the abstract of 2007 European Society of Regional Anesthesia. The effect is longer and more than that of transversus abdominis plane block because it works close to the spinal cord nerves. The QL block can be an effective pain control method for patients who underwent ileostomy closure. The aim of this study is to compare pain intensity after ileostomy closure between QL block (ropivacaine) group and placebo group (normal saline).
Transabdominal cerclage is an effective surgical intervention for preterm birth prevention. Placement of cervical sutures using a port closure device for prepregnancy laparoscopic abdominal cerclage has been used at our unit in recent years. We report the operative and pregnancy outcomes for prepregnancy laparoscopic abdominal cerclage using the port closure device and compare it with the outcomes of the traditional approach. For prepregnancy laparoscopic transabdominal cerclage (n=52), the port closure device approach was associated with less blood loss during surgery (0.95±4.4 mL vs 5.4±15.7 mL; P=.007) and a shorter hospital length of stay (0.0; 0.0-0.0 days vs 1.0; 0.0-1.0 days; P<.001). There were also trends toward shorter operating times (41.4±15.3 minutes vs 50.1±18.0 minutes; P=.167) and lower perioperative complication rates (0.0%; 0/21 vs 16.1%; 5/31; P=.065) when compared with the traditional technique. There was no significant difference between the port closure device technique and the traditional approach in the rate of preterm birth in a subsequent pregnancy (0.0%; 0/9 vs 22.6%; 7/39; P=.248). Use of the port closure device for suture placement during prepregnancy laparoscopic cerclage for preterm birth prevention was reported. This technique was associated with less blood loss and a shorter hospital length of stay, had trends toward shorter operating times and lower perioperative complication rates, and had similar rates of preterm birth.
Buprenorphine maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID (4 tablets QID) or to the highest level tolerated. Following this initial titration attempt, all subjects will have their buprenorphine dose reduced by 50% and lofexidine titration efforts will resume.
High mortality rates are commonly found in critically ill patients with tuberculosis (TB), which is due partially to limitations in the existing prognostic evaluation methods. Therefore, we aimed to find more effective prognostic evaluation tools to reduce the mortality rate. Data from critically ill patients with TB admitted to the intensive care unit of The Second Hospital of Nanjing, Nanjing, China, between January 2020 and December 2022 were analyzed retrospectively. A total of 115 patients were enrolled and divided into a survival group (n = 62) and a death group (n = 53) according to 30-day survival. Univariate and least absolute shrinkage and selection operator (LASSO) regression analyses were used to investigate the risk factors for 30-day death in critically ill patients with TB. A prediction model for risk of 30-day mortality was developed for critically ill patients with TB in the intensive care unit. The LASSO regression model showed that the prognostic nutritional index (PNI) and Acute Physiology and Chronic Health Status (APACHE II) scores on the third day after admission to the intensive care unit were independent risk factors for 30-day mortality in critically ill patients with TB (P <0.05). The area under the curve value and that PA3 represents the combination of the PNI and APACHE II score on the third day, which was 0.952 (95% CI: 0.913-0.991, P <0.001), was significantly higher than that of the PNI or the APACHE II score on the third day. The new model is as follows: PA3 = APACHE II score (on the third day) × 0.421 - PNI × 0.204. The PNI combined with the APACHE II score on the third day could well predict the 30-day mortality risk of critically ill patients with TB.
Accidental intravascular injection of SEPTOCAINE may be associated with convulsions, followed by central nervous system or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Dental practitioners who employ local anesthetic agents including SEPTOCAINE should be well versed in diagnosis and management of emergencies that may arise from their use. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. To avoid intravascular injection, aspiration should be performed before SEPTOCAINE is injected. The needle must be repositioned until no return of blood can be elicited by aspiration. Note, however, that the absence of blood in the syringe does not guarantee that intravascular injection has been avoided.

Small doses of local anesthetics injected in dental blocks may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injections of larger doses. Confusion, convulsions, respiratory depression or respiratory arrest, and cardiovascular stimulation or depression have been reported. These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation. Patients receiving these blocks should be observed constantly. Resuscitative equipment and personnel for treating adverse reactions should be immediately available. Dosage recommendations should not be exceeded [see Dosage and Administration (2.1)].
Patients who are planned for complex PCI requiring 7 or more French sheath and guiding catheters. Fluoroscopy guided femoral access will be used.